Analysts Project Improved Earnings for SpringWorks Amid Investor Caution Financial analysts expect SpringWorks Therapeutics to narrow its annual loss from $2.05 to $0.13 per share in the coming year, signaling optimism about future performance. However, a recent 9.96% rise in short interest highlights lingering skepticism, as over 12% of the float is now sold short, reflecting mixed investor sentiment.12